ASX Announcements

2022

29 April 2022 – Bonus Options Issue – Letter to Shareholders

28 April 2022 – ANP Quarterly Update & Appendix 4C

14 April 2022 – Receipt of R&D Tax Incentive payment

12 April 2022 – ANP – Prospectus – Options

12 April 2022 – Bonus Option Offer

14 March 2022 – Significant modulation of two bone morphogenetic proteins supports potential of ATL1102 for improving bone density in DMD

1 March 2022 – Poster Presentation at 2022 MDA Clinical & Scientific Conference

24 February 2022 – Long COVID-19 strategic collaboration with US Experts

23 February 2022 – Half Yearly Report and Accounts

8 February 2022 – ATL1102 MCRI Collaboration Dosing Commenced

27 January 2022 – Quarterly Update and Apendix 4C

2021

22 December 2022 – Change of Director’s Interest Notice (MD)

22 December 2021 – Entitlement Offer results

15 December 2021 – Results of Annual General Meeting

15 December 2021 – ANP – AGM Presentation

14 December – 2021 – Positive PIP Decision from UK MHRA & ratification of PDCO opinion by EMA

9 December 2021 – ATL1102 Toxicology Protocol submitted to US FDA

23 November 2021 – Entitlement Offer extension

15 November 2021 – Notice of Meeting & Proxy Form

5 November 2021 – Prospectus

5 November 2021 – Application for Quotation of Securities – Appendix 2A

5 November 2021 – Placement & Cleansing Notice

1 November 2021 – Investor Presentation 1 Nov 2021

1 November 2021 – Appendix 3B

1 November 2021 – Positive PDCO Opinion & $20M Placement

29 October 2021 – 2021 Annual Report

29 October 2021 – Appendix 4G & Governance Statement 2021

29 October 2021 – Quarterly Update and Apendix 4C

4 October 2021 – Antisense Therapeutics appoints new Non-Executive Director

30 September 2021 – Positive feedback received on Paediatric Investigation Plan

24 September 2021 – Statistically significant modulation in two DMD disease modifier proteins supports potential of ATL1102 in ambulant DMD and fibrotic conditions

20 September 2021 – New ATL1102 proteomics data to be presented in a Late Breaking News Abstract at the World Muscle Society 2021 Virtual Congress

25 August 2021 – Appendix 4E – Audited Financial Report Year Ended 30 June 2021

24 August 2021 –  ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA

12 August 2021 – ANP Updates on US Regulatory Plans for ATL1102 in DMD

28 July 2021 –Antisense Therapeutics transitions to new Board Chair

28 June 2021 – Antisense Therapeutics and Murdoch Children’s Research Institute enter into new R&D collaboration to further explore ATL1102 use in multiple muscle diseases

22 June 2021 – ATL1102 for DMD EMA PIP feedback and FDA regulatory progress

1 June 2021 –  US FDA Feedback on Type C Meeting for ATL1102 in the US

26 May 2021 – Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD

28 April 2021 – Quarterly Report & Appendix 4C_March 2021

23 April 2021 – ATL1102 FDA Type C meeting

24 March 2021 – Director’s Initial Interest Notice

22 March 2021 – Appointment of new Non-Executive Director

19 March 2021 – Appendix 3G

4 March 2021 – FDA Rare Disease Day

26 February 2021 – Jett Foundation Rare Disease Day

25 February 2021 – Paediatric Investigation Plan for ATL1102 in DMD submitted to European Medicines Agency

24 February 2021 – Appointment of Joint Company Secretary

24 February 2021 – Half Yearly Report and Half Year Accounts

15 February 2021 – Antisense Therapeutics granted Type C meeting with US FDA for ATL1102 in DMD

28 January 2021 – Appendix 4C & Quarterly Report_31 Dec 20 QTR_Final

Menu